"Eli Lilly ( ) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company's overall revenue growth in the midst of intense demand for obesity therapies. In a head-to-head Phase 3 trial, Zepbound demonstrated superior efficacy, with patients achieving 20.2% average weight loss over 72 weeks compared to 13.7% for Novo Nordisk 's ( ) Wegovy."
"In the Phase 3 ATTAIN-MAINTAIN trial Lilly announced yesterday, orforglipron helped patients maintain most of their prior weight loss after switching from injectable therapies. Patients who had completed 72 weeks on the highest doses of either Zepbound or Wegovy were randomized to orforglipron or a placebo for 52 weeks. Those switching from Wegovy to orforglipron regained an average of just 2 pounds, while patients switching from Zepbound regained an average of about 11 pounds."
Eli Lilly's Zepbound injection generated strong sales and drove company revenue growth amid high demand for obesity therapies. Zepbound produced 20.2% average weight loss over 72 weeks versus 13.7% for Wegovy in a head-to-head Phase 3 trial. Zepbound's dual GLP-1/GIP receptor targeting is credited for the efficacy advantage and market-share gains while Novo Nordisk reported slower growth and reduced 2025 guidance. Lilly submitted an NDA to the FDA for orforglipron, a once-daily oral GLP-1 receptor agonist, after positive Phase 3 results. The ATTAIN-MAINTAIN trial showed effective weight-loss maintenance when switching from injectables, with a safety profile consistent with the GLP-1 class.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]